Aldeyra Therapeutics(ALDX)

OYang10-28 19:28

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 宣布酒精性肝炎二期临床试验结果积极，聚焦下一代分子 RASP 产品候选管线
相对于基线，用于酒精相关肝病的信号发现分子 ADX‑629 在肝功能方面显示出统计学上的显著改善
ADX-629，一种用于概念验证临床试验的信号发现 RASP 调节剂，在一项针对四...查看全文

OYang08-28 22:22

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 获得欧洲药品管理局对 ADX-2191 用于治疗免疫特权部位原发性大 B 细胞淋巴瘤的孤儿药认定，包括原发性视网膜脉络膜淋巴瘤查看全文

OYang08-19 21:41

#药闻简讯# $Aldeyra Therapeutics(ALDX)$ 公司获得ADX-2191治疗视网膜色素变性的快速通道指定。查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)08-16 04:15

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-109391  Size: 4 KB 网页链接查看全文

季度财报

Aldeyra Therapeutics(ALDX)11-06 05:25

$Aldeyra Therapeutics(ALDX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-266989  Act: 34  Size: 8 MB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)08-14 06:05

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-108210  Size: 5 KB 网页链接查看全文

其他

Aldeyra Therapeutics(ALDX)08-15 04:35

$Aldeyra Therapeutics(ALDX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000950170-25-108920  Act: 34  Size: 10 KB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)08-19 19:05

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, item 9.01 Accession Number: 0000950170-25-109932  Act: 34  Size: 275 KB 网页链接查看全文

证券出售报告

Aldeyra Therapeutics(ALDX)08-13 05:55

$Aldeyra Therapeutics(ALDX)$ 144 Report of proposed sale of securities Accession Number: 0001836354-25-000003  Act: 33  Size: 4 KB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)10-28 19:05

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-25-252200  Act: 34  Size: 486 KB 网页链接查看全文

SeekingBiotech2022-12-01 22:20

ALDX Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA.
Plans to submit an NDA as soon as EOY. Intends to Request Priority Review.$Aldeyra Therapeutics(ALDX)$查看全文

当期报告

Aldeyra Therapeutics(ALDX)2022-11-29 21:12

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001157523-22-001684  Act: 34  Size: 192 KB 网页链接查看全文

季度财报

Aldeyra Therapeutics(ALDX)2022-11-11 05:13

$Aldeyra Therapeutics(ALDX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-22-024434  Act: 34  Size: 7 MB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)2022-11-10 20:12

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001157523-22-001587  Act: 34  Size: 342 KB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)2022-10-06 19:12

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001157523-22-001289  Act: 34  Size: 3 MB 网页链接查看全文

当期报告

Aldeyra Therapeutics(ALDX)2022-09-14 20:12

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001157523-22-001225  Act: 34  Size: 193 KB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)2022-08-12 04:19

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-22-017733  Size: 11 KB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)2022-08-11 04:18

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-22-017623  Size: 9 KB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)2022-08-10 04:19

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-22-017559  Size: 9 KB 网页链接查看全文

持股变动声明

Aldeyra Therapeutics(ALDX)2022-08-09 04:18

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-22-017481  Size: 9 KB 网页链接查看全文

Aldeyra Therapeutics2025财年年报业绩会议总结

一、开场介绍 会议时间： 未明确提及具体日期
主持人说明： 会议为HC Wainwright全球投资会议，由该公司资深生物技术分析师Matthew Caufield主持，目的是与Aldeyra Therapeutics公司CEO Todd Brady讨论公司管线进展。
管理层发言摘要： Todd Brady（CEO）：重点介绍了公司主要候...

Aldeyra Therapeutics2025财年年报业绩会议总结

一、开场介绍 会议时间： H.C. Wainwright第五届年度眼科会议
主持人说明： Matthew Caufield介绍会议目的，欢迎Aldeyra Therapeutics首席执行官Todd Brady博士参与讨论。
管理层发言摘要： Todd Brady强调公司从眼科起步的免疫学平台定位，重点介绍RASP（活性醛类物质）调节技...

季度财报

$Aldeyra Therapeutics(ALDX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-266989  Act: 34  Size: 8 MB 网页链接

当期报告

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-25-252200  Act: 34  Size: 486 KB 网页链接

当期报告

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, item 9.01 Accession Number: 0000950170-25-109932  Act: 34  Size: 275 KB 网页链接

持股变动声明

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-109391  Size: 4 KB 网页链接

其他

$Aldeyra Therapeutics(ALDX)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000950170-25-108920  Act: 34  Size: 10 KB 网页链接

持股变动声明

$Aldeyra Therapeutics(ALDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-108210  Size: 5 KB 网页链接

证券出售报告

$Aldeyra Therapeutics(ALDX)$ 144 Report of proposed sale of securities Accession Number: 0001836354-25-000003  Act: 33  Size: 4 KB 网页链接

季度财报

$Aldeyra Therapeutics(ALDX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-25-104971  Act: 34  Size: 8 MB 网页链接

当期报告

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-25-064869  Act: 34  Size: 217 KB 网页链接

当期报告

$Aldeyra Therapeutics(ALDX)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001213900-25-058035  Act: 34  Size: 232 KB 网页链接